spiro[cyclohexane-1,4'-quinazoline]-2'(3'H)-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: spiro[cyclohexane-1,4'-quinazoline]-2'(3'H)-one
• 英文别名: Spiro[1,3-dihydroquinazoline-4,1'-cyclohexane]-2-one
• 化学式: C₁₃H₁₆N₂O
• 分子量: 216.283
• InChiKey: ZGVAHJCPAGIFMR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  苯基脲 、 环己酮 在 PPA 作用下， 生成 spiro[cyclohexane-1,4'-quinazoline]-2'(3'H)-one
  参考文献：
  名称：

  Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1

  摘要：

  The synthesis and SAR studies of spiroquinazolinones as novel PDE7 inhibitors are discussed. The best compounds from the series displayed nanomolar inhibitory affinity and were selective versus other PDE isoenzymes. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.07.011

文献信息

• USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS
  申请人：Omeros Corporation

  公开号：EP2427193A1

  公开（公告）日：2012-03-14
• TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS
  申请人：Omeros Corporation

  公开号：EP2640395A2

  公开（公告）日：2013-09-25
• [EN] USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS<br/>[FR] UTILISATION D'INHIBITEURS DE PDE7 POUR LE TRAITEMENT DE TROUBLES DU MOUVEMENT
  申请人：OMEROS CORP

  公开号：WO2010129036A1

  公开（公告）日：2010-11-11

  A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE7 inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act.
• [EN] TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS<br/>[FR] TRAITEMENT D'ADDICTION ET DE TROUBLES DE CONTRÔLE DES IMPULSIONS AU MOYEN D'INHIBITEURS DE LA PDE7
  申请人：OMEROS CORP

  公开号：WO2012064667A2

  公开（公告）日：2012-05-18

  This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.
• [EN] TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS<br/>[FR] TRAITEMENT DE LA DÉPENDANCE ET DES TROUBLES DU CONTRÔLE DES IMPULSIONS À L'AIDE D'INHIBITEURS DE PDE7
  申请人：OMEROS CORP

  公开号：WO2013176877A2

  公开（公告）日：2013-11-28

  This disclosure is directed to treatment of addictions and primary impulse- control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.